155 related articles for article (PubMed ID: 35072852)
1. Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.
Shibahara H; Shiroiwa T; Ishiguro M; Nakamura M; Hasegawa J; Yamaguchi S; Masuda Y; Sakamoto J; Tomita N; Fukuda T
Eur J Health Econ; 2022 Sep; 23(7):1159-1171. PubMed ID: 35072852
[TBL] [Abstract][Full Text] [Related]
2. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
Ayvaci MU; Shi J; Alagoz O; Lubner SJ
Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
Tan SX; Pumpalova Y; Rogers AM; Bhatt K; Herbst CL; Ruff P; Neugut AI; Hur C
Cancer Med; 2023 Jul; 12(14):15515-15529. PubMed ID: 37318753
[TBL] [Abstract][Full Text] [Related]
8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
10. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
12. Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals.
Pumpalova Y; Rogers AM; Tan SX; Herbst CL; Ruff P; Neugut AI; Hur C
JCO Glob Oncol; 2021 Dec; 7():1730-1741. PubMed ID: 34936375
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
19. Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
Minami K; Morita M; Emi Y; Okamoto M; Tanaka E; Nagata S; Touyama T; Ohgaki K; Tanaka T; Okumura H; Suenaga T; Tokunaga S; Oki E; Kakeji Y; Akagi Y; Baba H; Natsugoe S; Maehara Y;
Int J Clin Oncol; 2017 Jun; 22(3):505-510. PubMed ID: 28101757
[TBL] [Abstract][Full Text] [Related]
20. Effect of the duration of the capecitabine regimen following colon cancer surgery in an elderly population: a retrospective cohort study.
Chen W; Dong H; Wang G; Chen J; Wang W
World J Surg Oncol; 2021 Aug; 19(1):238. PubMed ID: 34380513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]